Rutkowski Piotr, Kozak Katarzyna
Department of Soft Tissue/Bone Sarcoma and Melanoma; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, Warsaw, 02-781, Poland.
BMC Med. 2017 Mar 17;15(1):57. doi: 10.1186/s12916-017-0826-4.
During the European Cancer Congress, the melanoma sessions focused on practice changing trials. Recent developments and approvals in immunotherapy and targeted agents have significantly changed the landscape of melanoma therapy in the metastatic setting and provide great promise for adjuvant and neoadjuvant treatment in high-risk locoregional disease. Perioperative (combined pre- and postoperative) strategies may be extremely beneficial for patients with bulky stage IIIC disease. The long-term results of the European Organisation for Research and Treatment of Cancer (EORTC) 18071 adjuvant trial ipilimumab versus placebo after complete resection of high-risk stage III melanoma, demonstrating improvement in overall survival, has established the reference bar for further trials with postoperative therapy.
在欧洲癌症大会期间，黑色素瘤会议聚焦于改变实践的试验。免疫疗法和靶向药物的最新进展及获批情况已显著改变了转移性黑色素瘤治疗的格局，并为高危局部区域疾病的辅助和新辅助治疗带来了巨大希望。围手术期（术前和术后联合）策略对于IIIC期肿块较大的患者可能极为有益。欧洲癌症研究与治疗组织（EORTC）18071辅助试验对高危III期黑色素瘤完全切除术后使用伊匹单抗与安慰剂进行比较，其长期结果显示总生存期有所改善，这为术后治疗的进一步试验确立了参考标准。
